All
Avoiding steroidal addiction: Consider calcineurin inhibitors first
August 31st 2009Sheffield, England - New research data demonstrates that mild, moderate and potent strengths of topical corticosteroids (TCS) cause a thinning of the stratum corneum, particularly when applied for longer periods of time, whereas topical calcineurin inhibitors show no negative change in the integrity of the skin barrier.
The truth about topicals: Effectiveness of anti-aging agents revealed
August 31st 2009High Point, N.C. - The public is being inundated with advertisements about expensive topical agents that purport to have anti-aging properties. However, dermatologists can help their patients be savvy consumers by demystifying the manufacturers? claims.
Activating cutaneous vitamin D: Low-dose UVB strengthens epidermal barrier, antimicrobial function
August 31st 2009Wonju, South Korea - While high-dose UVB is detrimental to the epidermal permeability barrier, low-dose UVB can be therapeutic in mending a defective epidermal barrier and antimicrobial function, such as in atopic dermatitis, according to one dermatologist.
Neck rejuvenation: Fractional CO2 laser is valuable tool
August 26th 2009A clinical trial evaluating neck rejuvenation using an ablative fractional CO2 laser showed all patients (n = 13) achieved at least 25 percent improvement in rhytids, crepe-like skin, neck tightness, and pigmentation. There were no problems with scarring or pigmentary changes.
Fear not: Botox safety concerns overstated, expert says
August 26th 2009Las Vegas - Although some recent animal research and human case reports have spurred concerns regarding the safety of Botox Cosmetic (botulinum toxin A, Allergan), one of the product's pioneers says that Botox remains safe when used as directed for cosmetic indications.
Botox and hyperhidrosis: Gold standard for treating underarms
August 26th 2009Botulinum toxin type A (Botox Allergan) is the gold standard to treat axillary hyperhidrosis, but it also can be administered to treat palmar hyperhidrosis or plantar hyperhidrosis. In very rare instances, it can be used to treat the mid-face. There is not a standard dosing schedule in using botulinum toxin type A to treat hyperhidrosis.
Under suspension: Suture lift technique permits retention of facial tissue
August 14th 2009Augusta, Ga. - A new technique for soft-tissue suture lifting in the face is an alternative to the minimally invasive facelift. The technique uses clear, modified polypropylene with bio-absorbable cones and multiple point fixations, says Gloria Mabel Gamboa, M.D., F.A.C.S., associate professor at the Medical College of Georgia in Augusta, Ga.
Laser update: Fractionated devices, wavelength combinations drive surgery segment
August 14th 2009Washington - Over the next five years, fractionated lasers and combined-wavelength treatments will continue to lead growth in the dermatologic laser surgery segment, according to a leading dermatologic laser surgeon.
Hyperhidrosis in teens: Multicenter prospective study validates use of botulinum toxin
August 10th 2009Intradermal injection of onabotulinumtoxinA (Botox, Allergan) is a safe, effective and well-tolerated treatment for primary axillary hyperhidrosis in adolescent patients, according to the findings of a prospective, multicenter Phase 4 study.
Managing UV-induced pigmentary disorders: New, affordable products complement sunscreen
August 6th 2009Boston - Patients and dermatologists have new options in the management of pigmentary disorders resulting from decades of sun exposure, according to Ranella A. Hirsch, M.D., clinical assistant professor of dermatology, Boston University Medical Center.
Extension set for "Red Flags" rule
August 6th 2009Physicians have received yet another extension in the deadline for complying with the "Red Flags" rule requiring programs to guard against identity theft. The Federal Trade Commission (FTC), the agency which developed the rule and is responsible for implementing it, announced in late July that it was moving the deadline for compliance from August 1 to November 1.
Nevi of special site: Conservative treatment approach justified
August 5th 2009Nevi of special site can be seen not only in children and adolescents, but in adults up to age 35 as well, according to a recent study. A conservative approach to treating these nevi is justified given they do not appear to have the potential for malignancy.
TNF blockers boost risk of lymphoma, FDA says
August 5th 2009Washington - The Food and Drug Administration (FDA) says an increased risk of lymphoma and other cancers is associated with the use of drugs like Remicade (Centocor) and Humira (Abbott) in children and adolescents, the Wall Street Journal reports.
FDA adds warning for Botox, similar products; changes generic names
August 4th 2009Washington - The Food and Drug Administration (FDA) has approved a new warning on Allergan's Botox and a similar product about the possibility of life-threatening breathing and swallowing problems, following up on an earlier announcement about tougher warnings.
Unique development: Pyoderma gangrenosum appear during ulcerative colitis
August 4th 2009In a recent case study, a patient receiving infliximab for the treatment of ulcerative colitis paradoxically developed widespread pyoderma gangrenosum lesions, a disease which normally responds well to this biologic therapy.